<DOC>
	<DOCNO>NCT03045770</DOCNO>
	<brief_summary>The aim study compare efficacy safety mFOLFOX , mFOLFIRI FOLFPTX first-line treatment AGC EGJA .</brief_summary>
	<brief_title>mFOLFOX Versus mFOLFIRI Versus FOLFPTX First-line Treatment AGC EGJA</brief_title>
	<detailed_description>In previous study , find mFOLFOX ( Combination Oxaliplatin , Fluorouracil ) , mFOLFIRI ( Combination Irinotecan , Fluorouracil ) , FOLFPTX ( Combination Paclitaxel , Fluorouracil ) active patient AGC EGJA.This study do find one best efficacy .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>1 . Age：18~70years . 2 . Subjects Histologically cytologically confirm advanced metastatic gastric cancer adenocarcinoma gastroesophageal junction . 3 . Firstline treatment patient . 4. subject least one measurable lesion define RECIST ( version 1.1 ) . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 6 . Survival expectation≥ 3 month . 7 . No serious concomitant disease ( include heart , lung , liver jaundice gastrointestinal obstruction ) . 8 . Adequate organ function define indicated below： （1）Adequate bone marrow function , define : ( blood transfusion within 14 day ) 1 . Hemoglobin ( Hb ) ≥80g/L， 2 . White blood count ( WBC ) ≥3.5×109/L 3 . Absolute neutrophil count ( ANC ) ≥1.5×109/L， 4 . Platelet count ( PLT ) ≥75×109/L； （2）Adequate liver function , define : 1 . Bilirubin ≤1.5×the upper limit normal ( ULN ) 2 . Alanine aminotransferase ( ALT ) , Aspartate aminotransferase ( AST ) ≤3.0× ( ULN ) , Glutamyl transpeptidase ( GGT ) ≤2.5× ( ULN ) , ( When liver metastasis , ALT AST GPT &lt; 5.0× ( ULN ) ) . 3. serum creatinine ≤1.0×（ULN） , creatinine clearance &gt; 50 mL/min ( calculate per Cockcroft Gault formula ) 9 . Females childbearing potential must pregnancy test 7 day participate ( include serum urine ) , result negative , Females childbearing potential must agree use highly effective method contraception throughout entire study period 8 week study drug discontinuation . Male subject must successful vasectomy female partner must meet criterion ( i.e.not childbearing potential practicing highly effective contraception throughout study period 8 week study drug discontinuation ) . 10 . Subjects provide write informed consent participating , Willing able comply aspect protocol . 1 . Females lactate pregnant Screening Baseline . 2 . Patients active malignancy ( except definitively treat melanoma insitu , basal squamous cell carcinoma skin , carcinoma insitu cervix ) . 3 . Patients receive previous pre postoperative chemotherapy chemoradiation ineligible therapy complete less 6 month prior study registration . Patients must recover adverse event previous therapy . 4 . Patients brain central nervous system metastasis , include leptomeningeal disease . 5 . Significant cardiac disease define : unstable angina , New York Heart Association ( NYHA ) grade II great , congestive heart failure , history myocardial infarction within 6 month Evidence bleed diathesis coagulopathy . 6 . History stroke CVA within 6 month . 7 . Inability comply study and/or followup procedure . 8 . Patients condition opinion investigator would preclude his/her participation clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>